Co-Diagnostics Showcases Innovative PCR Platform at BioUtah's Life Sciences Day on the Hill

Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for developing molecular diagnostic tests, is set to exhibit at BioUtah's 2025 Life Sciences Day on the Hill. The event, taking place on January 30, 2025, at the Utah State Capitol Rotunda, will feature over 25 Utah life sciences companies showcasing their innovative healthcare products and engaging directly with legislators to highlight the importance of the industry.

Co-Dx will showcase its upcoming at-home and point-of-care Co-Dx PCR testing platform, designed for the detection of infectious diseases such as COVID-19, influenza, RSV, HPV, and tuberculosis. The platform incorporates cloud-based analysis capabilities to help build situational awareness and provide support for tracking infectious disease outbreaks at the community and regional level, all operated via an intuitive smartphone interface.

The Co-Dx PCR platform is currently under review by the FDA and other regulatory bodies and is not yet available for sale. However, the Company's Emergency Use Authorization submission for the new Co-Dx PCR Pro instrument and COVID-19 test kit, designed for point-of-care and at-home use, is under review by the FDA. The menu of tests in development for the platform includes TB, HPV, and a multiplex respiratory panel for flu A/B, COVID-19, and RSV.

Co-Diagnostics' participation in BioUtah's Life Sciences Day on the Hill aligns with its long-term growth strategy, as it allows the company to showcase its innovative products and engage with key stakeholders in the life sciences industry. By exhibiting at the event, Co-Diagnostics can strengthen global and local relationships, demonstrate its cutting-edge technology, gain exposure and recognition, engage with policymakers, and potentially form collaborations or partnerships with other life sciences companies.

The diverse range of Utah life sciences companies exhibiting at the event presents opportunities for collaboration and partnerships, as Co-Diagnostics' presence contributes to the state's growing life sciences industry. Potential partners could include ARUP Laboratories, BD (Becton, Dickinson and Company), BioMerieux Inc., and Intermountain Health, among others. These partnerships could help Co-Diagnostics expand its market reach, enhance its product offerings, and strengthen its position in the growing Utah life sciences industry.

In conclusion, Co-Diagnostics' participation in BioUtah's Life Sciences Day on the Hill is a strategic move that aligns with the company's long-term growth objectives. By showcasing its innovative PCR platform and engaging with key stakeholders, Co-Diagnostics can enhance its visibility, form strategic partnerships, and contribute to the growth of Utah's life sciences industry. As the company awaits regulatory approval for its PCR platform, investors should monitor its progress and potential collaborations that may arise from this event.